Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vero cell-derived influenza vaccine efficacy study
NCT00800605Phase 3Completed
- Sponsor
- Resilience Government Services
- Start
- Dec 2008
- Primary completion
- May 2009
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Butantan Influenza Trivalent, Fragmented and Inactivated in influenza (2 arms), sponsored by Resilience Government Services. Primary endpoint: Efficacy of an Investigational Vero Cell-derived Influenza Vaccine to Prevent Infection With an Influenza Virus That is Antigenically Similar to One of the Three Strains in the Vaccine at 180 days. Started Dec 2008; status: completed.
02
Drugs
Butantan Influenza Trivalent, Fragmented and Inactivated
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00800605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00800605.